BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20213081)

  • 1. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
    Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
    Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance analysis of the PALB2 c.1592delT founder mutation.
    Erkko H; Dowty JG; Nikkilä J; Syrjäkoski K; Mannermaa A; Pylkäs K; Southey MC; Holli K; Kallioniemi A; Jukkola-Vuorinen A; Kataja V; Kosma VM; Xia B; Livingston DM; Winqvist R; Hopper JL
    Clin Cancer Res; 2008 Jul; 14(14):4667-71. PubMed ID: 18628482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
    Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
    Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
    Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
    Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
    Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
    Choi DH; Lee MH; Bale AE; Carter D; Haffty BG
    J Clin Oncol; 2004 May; 22(9):1638-45. PubMed ID: 15117986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
    Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D
    Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
    Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
    Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
    Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
    Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.